Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.

Detalles Bibliográficos
Autores principales: Anderson, Timothy S., O’Donoghue, Ashley, Mechanic, Oren, Dechen, Tenzin, Stevens, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425149/
https://www.ncbi.nlm.nih.gov/pubmed/36036937
http://dx.doi.org/10.1001/jamanetworkopen.2022.28997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425149/
https://www.ncbi.nlm.nih.gov/pubmed/36036937
http://dx.doi.org/10.1001/jamanetworkopen.2022.28997

Ejemplares similares